Results 41 to 50 of about 3,550,326 (312)

Clinical and Biological Features of Response in Resistant Neuroblastoma to 131I‐Metaiodobenzylguanidine Radiotherapy in the Anti‐GD2 Immunotherapy Era

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background 131I‐metaiodobenzylguanidine (131I‐MIBG) radiotherapy is a key treatment for relapsed and refractory (R/R) neuroblastoma (NB). Patients with R/R disease treated in the modern era are increasingly exposed to anti‐GD2 immunotherapy, which exerts selective pressure and may modify both tumor cell state and microenvironment.
Benjamin J. Lerman, Katherine K. Matthay, Fabienne Hollinger, Catriona Black, Ann A. Lazar, Miguel Pampaloni, Steven G. DuBois, Kieuhoa T. Vo   +7 more
wiley   +1 more source

RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer.

, 2019
PURPOSE: Metastatic castration-resistant prostate cancer (mCRPC) is a lethal but clinically heterogeneous disease, with patients having variable benefit from endocrine and cytotoxic treatments.
Crespo, M, Makay, A, Rescigno, P, Mateo, J, Sharp, A, Romanel, A, McNair, C, Riisnaes, R, Carreira, S, Nava Rodrigues, D, Knudsen, K, Demichelis, F, de Bono, JS, Casiraghi, N, Miranda, S, Figueiredo, I, Sumanasuriya, S, Schiewer, M, Boysen, G, Gasperini, P   +19 more
core   +1 more source

The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer [PDF]

, 2008
Ovarian cancer is the most frequent cause of death from gynaecological cancer in the Western world. Current prognostic factors do not allow reliable prediction of response to chemotherapy and survival for individual ovarian cancer patients.
de Bock, G. H., A P G Crijns, Hollema, H., P de Graeff, de Bock, G.H.; id_orcid, de Vries, E.G.; id_orcid, Crijns, A.P.G., G H de Bock, de Bock, G.H., A G J van der Zee, Bartlett, J.M., H G Klip, S de Jong, de Graeff, P., J M Bartlett, van der Zee, A. G. J., Crijns, A. P. G., ten Hoor, K.A., de Vries, E.G.E., van der Zee, A.G.J., Wisman, G.B., ten Hoor, K. A., de Vries, E. G. E., Bartlett, J. M., H Hollema, K A ten Hoor, Klip, H. G., G B A Wisman, de Jong, S., Wisman, G. B. A., Klip, H.G., van der Zee, A.G., de Jong, S.; id_orcid, Crijns, A.P., K Oien, Oien, K., Wisman, G.B.A., de Vries, E.G., E G E de Vries   +38 more
core   +1 more source

Venous Thromboembolism in Pediatric Bone Sarcoma Patients: A 10‐Year, Single‐Institution Experience Encompassing the COVID‐19 Pandemic

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Osteosarcoma (OS) and Ewing sarcoma (EWS) are the most common primary bone cancers in children, but acute thrombosis is poorly characterized in this population. Our study evaluated the rates of venous thromboembolism (VTE) and associated risk factors in pediatric patients with bone sarcomas treated over a 10‐year period encompassing
Sarah Kappa, Shou Xu, Mark Zobeck, Sarah E. Sartain, Nino Rainusso, Lisa Wang, Nicole Montgomery, Paige Wheaton, Sarah Whittle   +8 more
wiley   +1 more source

EGFR T790M mutation after chemotherapy for small cell lung cancer transformation of EGFR-positive non-small cell lung cancer

Respiratory Medicine Case Reports, 2018
In non-small cell lung cancer (NSCLC) with an epidermal growth factor receptor (EGFR) mutation, 50%–65% of cases acquire resistance after treatment with EGFR-tyrosine kinase inhibitors (EGFR-TKIs) because of an EGFR T790M point mutation and 3%–14% of ...
Tomoaki Sonoda, Shingo Nishikawa, Rie Sakakibara, Masafumi Saiki, Ryo Ariyasu, Junji Koyama, Satoru Kitazono, Noriko Yanagitani, Atsushi Horiike, Fumiyoshi Ohyanagi, Hironori Ninomiya, Yuichi Ishikawa, Makoto Nishio   +12 more
doaj   +1 more source

The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial

, 2018
CDK4/6 inhibition with endocrine therapy is now a standard of care for advanced estrogen receptor-positive breast cancer. Mechanisms of CDK4/6 inhibitor resistance have been described preclinically, with limited evidence from clinical samples.
Liu, Y, Sibylle Loibl, Loi, S, Rosalind J. Cutts, Huang Bartlett, C, André, F, Fabrice André, Cynthia Huang Bartlett, Cutts, RJ, Nicholas C. Turner, Cristofanilli, M, Sarah Hrebien, Garcia-Murillas, I, Hrebien, S, Kerry Fenwick, Loibl, S, Fenwick, K, Yuan Liu, Huang, X, Sherene Loi, Turner, NC, Ben O'Leary, Isaac Garcia-Murillas, Massimo Cristofanilli, Xin Huang, O'Leary, B   +25 more
core   +1 more source

TIMP-3 as a therapeutic target for cancer [PDF]

Therapeutic Advances in Medical Oncology, 2019
Tissue inhibitor of metalloproteinase-3 (TIMP-3), a secreted glycoprotein, plays an important role in carcinogenesis. It can bind to many proteinases to suppress their activity and thus protect the extracellular matrix from degradation. TIMP-3 may have many anticancer properties, including apoptosis induction and antiproliferative, antiangiogenic, and ...
Chun-Wen Su, Chiao-Wen Lin, Wei-En Yang, Shun-Fa Yang   +3 more
openaire   +3 more sources

Serological Benefit of SARS‐CoV‐2 Vaccination Relative to Infection in Children With Acute Lymphoblastic Leukemia

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Children with acute lymphoblastic leukemia (ALL) are at risk of severe outcomes from SARS‐CoV‐2 (SCV2). In the post‐pandemic context, where most children have been infected with SCV2, there are limited data on whether vaccination remains beneficial in children with ALL.
Janna R. Shapiro, Freda Qi, Karen Colwill, Alina D. Dorogy, Ying Liu, Michelle Science, Anne‐Claude Gingras, James M. Rini, Sumit Gupta, Sarah Alexander, Shelly Bolotin, Tania H. Watts   +11 more
wiley   +1 more source

SAPHO syndrome with a purely osteolytic form: A case report

Radiology Case Reports, 2023
SAPHO (synovitis, acne, pustulosis, hyperostosis, and osteitis) syndrome is a rare, chronic autoinflammatory disorder that can present with a constellation of cutaneous and osteoarticular symptoms.
Akira Kakiuchi, MD, Yayoi Yamamoto, MD, PhD, Akira Kanbe, MD, Daichi Kojima, MD, Ayako Hino, MD, PhD, Ayumi Horikawa, MD, PhD, Tsunehiro Doiuchi, MD, Hiroaki Kurihara, MD, PhD   +7 more
doaj   +1 more source

Avis n°3 du Comité éthique et cancer : "Quelle réponses apporter aux demandes de DPI pour une forme héréditaire de cancer ? " [PDF]

, 2009
Avis n° 3 du Comité éthique et cancer, au sujet du diagnostic préimplantatoire pour les formes héréditaires de cancerComité éthique et cancer, avis n°3 du 14 mai 2009 « Quelle réponses apporter aux demandes de DPI pour une forme héréditaire de cancer ? »
Comité éthique et cancer, .
core